Liminatus Pharma Soars 11.9% on Digital Asset Strategy Review

On July 24, 2025, Liminatus Pharma's stock surged by 11.9% in pre-market trading, reflecting significant investor interest and optimism surrounding the company's recent strategic initiatives.

Liminatus Pharma has initiated a strategic review to explore the potential inclusion of regulated digital asset strategies within its treasury management framework. This move is part of the company's broader commitment to financial stewardship and balance sheet optimization, while maintaining its core focus on developing targeted cancer immunotherapies.

The company emphasized that this review is exploratory and no agreements regarding digital assets have been made. Any future steps would require approval from the Board of Directors and compliance with regulatory standards. Liminatus Pharma remains dedicated to its mission of advancing life-changing cancer therapies, ensuring that this financial strategy does not divert from its primary goal of improving patient outcomes.